Inpharma 1311 - 27 Oct 2001

■ Aspirin 160 mg/day is more effective than aspirin80 mg/day plus warfarin in the prevention of ischaemicstroke among patients who have recently experiencedan acute myocardial infarction (MI), reportinvestigators from the CARS* trial. In that study, 8803such patients were randomised to 1 of 3 groups:aspirin 160 mg/day; aspirin 80 mg/day plus warfarin 1mg/day; or aspirin 80 mg/day plus warfarin 3 mg/day.The results of that study have already beenpublished.** In the current analysis, the warfarin 1mg/day plus aspirin 80 mg/day arm (n = 2028) wascompared with the aspirin 160 mg/day arm (3393). At1 year, the incidence of ischaemic stroke was lower inaspirin monotherapy recipients, compared withwarfarin plus aspirin recipients (0.6 vs 1.1%, p =0.0534). Corresponding rates at 2 years were 0.9 and1.5%, respectively.* Coumadin Aspirin Reinfarction Study** see Inpharma 1100: 10, 16 Aug 1997; 800555024

O’Connor CM, et al. Comparison of two aspirin doses on ischemic stroke inpost-myocardial infarction patients in the warfarin (Coumadin) AspirinReinfarction Study (CARS). American Journal of Cardiology 88: 541-546, 1Sep 2001 800880059

1

Inpharma 27 Oct 2001 No. 13111173-8324/10/1311-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved